Allergan Reports Strong 2016 Finish with 7% Increase in GAAP Net Revenues to $3.9 Billion in Fourth Quarter 2016

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. AAPL
2. BRZE
3. TTAN
4. CHYM
5. USO
6. COO
7. IRT
8. QCOM
9. AEO
10. MSI

Go back to Allergan Reports Strong 2016 Finish with 7% Increase in GAAP Net Revenues to $3.9 Billion in Fourth Quarter 2016

Allergen (AGN) PT Raised to $280 at Leerink Partners Following 4Q

February 9, 2017 8:07 AM EST

Leerink Partners raised its price target on Allergen (NYSE: AGN) to $280.00 (from $271.00) while maintaining a Outperform rating.

Analyst Jason Gerberry commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic... More

Allergan (AGN) Tops Q4 EPS by 14c; Guides Above the Street

February 8, 2017 7:02 AM EST

Allergan (NYSE: AGN) reported Q4 EPS of $3.90, $0.14 better than the analyst estimate of $3.76. Revenue for the quarter came in at $3.86 billion versus the consensus estimate of $3.77 billion.

GUIDANCE:

Allergan sees FY2017 EPS of $15.80-$16.30, versus the consensus of $16.01. Allergan sees FY2017 revenue of $15.5-15.8 billion, versus the consensus of $15.37 billion.

"2016 was a year of transformation for Allergan. We are now a branded biopharmaceutical leader, focused on delivering... More